Monte Alto’s US$6 Billion NPV Now Depends on Camaçari Pilot Recoveries

Brazilian Rare Earths has moved its Monte Alto development case from bench-scale assumptions into a live processing test, commissioning the first stage of its Camaçari pilot plant just three weeks after publishing a scoping study with an after-tax NPV of about US$6 billion.

The September 8 milestone matters because the valuation now attached to Monte Alto depends less on finding more high-grade rock than on proving that unusually rich mineralisation can be beneficiated, leached and separated at repeatable recoveries and costs. Stage I has produced its first rare-earth mineral concentrate and will now run bulk campaigns to refine concentrate grade, recovery, equipment selection and operating assumptions for the pre-feasibility study.

Brazilian Rare Earths, or BRE, says SENAI CIMATEC and partner organisations will contribute R$6.4 million, about A$1.7 million, toward Stage II. That covers roughly 59% of expected Stage II capital and operating costs and lifts total co-funding for the pilot program to R$14.6 million. Detailed design is under way, equipment delivery is targeted for the fourth quarter of 2026 and commissioning is planned for the second quarter of 2027.

The second stage is the more important commercial test. It will add hydrometallurgical extraction and separation, with the aim of producing separated neodymium-praseodymium oxide, a heavy-rare-earth concentrate and uranium yellowcake. Carester, BRE’s French separation partner, will lead the separation workstream and help translate pilot data into engineering for the planned Camaçari refinery.

That sequencing is important because the August scoping study is unusually aggressive. BRE reported a 3.40 million-tonne Monte Alto resource grading 11.3% total rare-earth oxides, including 2.51 million tonnes in the indicated category at 12.7% TREO. The study forecasts average first-five-year production of about 6,351 tonnes a year of NdPr oxide and 2,502 tonnes of HRE+ concentrate containing roughly 274 tonnes a year of dysprosium and terbium, 360 tonnes of gadolinium and 1,060 tonnes of yttrium.

On the company’s assumptions, initial construction capital is about US$969 million including contingency, after-tax NPV8 is roughly US$6.0 billion, after-tax IRR is about 90% and payback is 1.1 years. Cash operating costs were placed at about US$21 per kilogram of NdPr equivalent, which BRE says would put the project in the first quartile of Benchmark Mineral Intelligence’s forecast global rare-earth cost curve.

Those numbers are possible because Monte Alto combines very high grades with a flowsheet designed to reject waste before chemical treatment. Earlier sensor-sorting tests upgraded feed from 12.4% TREO to around 27% TREO in a single pass, while cascade sorting recovered roughly 96% to 99% of contained rare earths into a product above 20% TREO. Separate acid-cure test work at 150°C reported total-system recoveries of about 92% for NdPr, up to 82% for dysprosium, terbium and yttrium, and 89% for uranium once ore sorting and downstream steps were included.

The pilot plant now has to show those results are reproducible on larger, variable feed rather than selected laboratory composites. That is the distinction between a technically attractive deposit and a financeable refinery. Reagent consumption, impurity loading, filtration behaviour, cycle times, equipment wear, product purity and recoveries across different ore domains can all move materially as throughput scales.

BRE also wants co-products to improve economics. The scoping study includes the cost of recovering uranium but assigns no uranium revenue; it forecasts about 540 tonnes a year of U3O8 during the first five run-rate years and 466 tonnes a year over the life of mine. Stage II will also test recovery routes for scandium, niobium, tantalum and titanium from process solutions and residues. Any payable co-product credits could lower the effective NdPr-equivalent cost, but none should be assumed until recovery, product specification and commercial terms are proven.

The downstream route has more substance than a generic development plan. Carester has a binding 10-year agreement to purchase BRE heavy-rare-earth concentrate containing up to 150 tonnes a year of dysprosium and terbium, with the material intended for its Caremag separation plant in France. The same group is also providing engineering and commissioning support for BRE’s planned Brazilian refinery.

Upstream permitting has also moved forward. Brazil’s National Mining Agency granted Monte Alto a trial mining licence in March allowing extraction of up to 2,000 tonnes a year for metallurgical work and customer samples. BRE’s pilot facility had already received its final nuclear-safety operating authorisation in September 2025, relevant because the planned flowsheet includes uranium-bearing material.

The balance sheet gives BRE room to run the current study program but does not fund a US$969 million development. The company reported A$134.4 million of cash at June 30, 2026, after exploration and evaluation spending accelerated during the half. That makes the pre-feasibility study, pilot results and eventual financing structure more important than another exploration headline.

Recent drilling still adds optionality. August step-outs returned 25.6 metres at 17.4% TREO, including 8 metres at 28.1%, south of the current resource envelope, while another hole intersected 9.4 metres at 21.8% TREO down dip. The current scoping case excludes drilling completed after the February resource cut-off, so successful conversion could extend mine life or support higher throughput.

Brazilian policy is moving in the same direction. The country is trying to retain more beneficiation and processing at home rather than remain an exporter of raw critical minerals, and recent legislation has proposed billions of reais of support for domestic processing and mineral-sector financing. Camaçari fits that agenda because it places separation and co-product recovery inside Brazil rather than exporting untreated ore.

For investors, the pilot plant is therefore more consequential than its modest physical scale suggests. Monte Alto’s headline resource grade is already exceptional. The investment case now hinges on whether BRE can reproduce laboratory recovery, control impurities and reagent costs, produce qualified oxide and concentrate products, and turn a US$6 billion scoping-study valuation into a bankable process design.

The next catalysts are operational rather than promotional: Stage I bulk-test results, updated PFS metallurgy, Stage II equipment delivery in the fourth quarter, and hydrometallurgical commissioning in the second quarter of 2027. If those milestones validate the current recovery and cost assumptions, BRE will have materially reduced the largest technical gap in its Monte Alto thesis. If they do not, the project’s extraordinary grade will not by itself rescue the economics.